Cell based therapies for Cancer: From bench to bedside
Khalid Shah, Director, Stem Cell Therapeutics and Imaging Program, Massachusetts General Hospital; Associate Professor, Harvard Medical School
Khalid Shah, professor at Harvard Medical School and director of the Stem Cell Therapeutics and Imaging Program at Massachusetts General Hospital, reviewed the lack of progress in treatment for glioblastoma multiforme over the last 25 years – a period which has seen only a 2-month increase in average survival, despite many promising pre-clinical publications. Having identified poor animal models as a major reason for this translational failure, Dr. Shah led the development of a clinically realistic mouse model for primary GBM treatment by resection. His group’s subsequent invention of a stem cell-enriched hydrogel that can be inserted into the resection cavity to eliminate residual tumor cells is now progressing rapidly towards clinical trials.